Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$74.55 USD
+0.53 (0.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $74.61 +0.06 (0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.55 USD
+0.53 (0.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $74.61 +0.06 (0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
by Zacks Equity Research
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's
by Zacks Equity Research
Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
Here's Why Doctor Reddy's (RDY) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Identify Stock Market Winners Early in 2024
by Bryan Hayes
With every year comes a different market theme.
Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Journey Medical (DERM) Up on Update for Skin Disease Candidate
by Zacks Equity Research
Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
by Zacks Equity Research
Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.
Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.